By Roger Lias
A new CEO’s observations on managing a fast-growing, fully integrated biopharmaceutical company from the other side of the world during a global pandemic.
I enjoy new challenges and am passionate about lowering the cost of valuable biologic medicines and improving access for needy patients throughout the world. I was excited then, at the end of 2019, to accept the role of CEO at Stelis Biopharma Pvt. Ltd., a company both developing an in-house portfolio of biosimilars and innovative biologics and also offering a comprehensive range of “end-to-end” contract development and manufacturing services via its Stelis BioSource division from world-class facilities located in Bangalore, India.